Get the tools used by (smart)2 investors.

Beneish M-Score for Regeneron Pharmaceuticals Inc

Join now and get access to the full platform

Search for company or ETF

 

  0 results available. Select is focused ,type to refine list, press Down to open the menu,

REGN: Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to trea...

- USD
Price
USD
Fair Value
Upside
- - -
52-week range

Analysis

Fiscal Years
Trailing Twelve Months
Fiscal Halfs
Fiscal Quarters
Daily
Hide this widget

The following section summarizes insights on Regeneron Pharmaceuticals Inc's Beneish M-Score:

Dec 2016Dec 2018Dec 2020Dec 2022Dec 2024-3.00-2.50-2.00-1.50

Performance Summary
  • Regeneron Pharmaceuticals's latest twelve months beneish m-score is -2.23
  • Regeneron Pharmaceuticals's beneish m-score for fiscal years ending December 2020 to 2024 averaged -2.21.
  • Regeneron Pharmaceuticals's operated at median beneish m-score of -2.36 from fiscal years ending December 2020 to 2024.
  • Looking back at the last 5 years, Regeneron Pharmaceuticals's beneish m-score peaked in December 2021 at -1.49.
  • Regeneron Pharmaceuticals's beneish m-score hit its 5-year low in December 2023 of -2.52.
  • Regeneron Pharmaceuticals's beneish m-score decreased in 2020 (-2.36, +6.6%), 2022 (-2.45, +64.4%), and 2023 (-2.52, +3.0%) and increased in 2021 (-1.49, -37.0%) and 2024 (-2.23, -11.7%).

How does Regeneron Pharma's Beneish M-Score benchmark against competitors?

Hide this widget

We've identified the following companies as similar to Regeneron Pharmaceuticals Inc because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the list to the ones listed below.

Metric Usage: Beneish M-Score

Hide this widget
beneish_mscore
Slug
number
Datatype
text
Format
current
Default Period
FY, LTM
Periods Supported
Free
Plan

To view the full list of supported financial metrics please see Complete Metrics Listing.

Similar Metrics

Search for metric or datapoint

Beneish M-Score

A statistical score that uses financial ratios to identify whether a company has manipulated its earnings

Definition of Beneish M-Score

Hide this widget

The Beneish M-Score statistical score that uses financial ratios to identify whether a company has manipulated its earnings. Regeneron Pharmaceuticals’s Beneish M-Score of −2.23 implies the company is not a likely earnings manipulator.

The Beneish M-Score outlines eight financial ratios required to calculate the score:

1) Days Sales in Receivables Index (DSRI)

DSRI = (Net Receivablest / Salest) / (Net Receivablest-1 / Salest-1)

2) Gross Margin Index (GMI)

GMI = [(Salest-1 - COGSt-1) / Salest-1] / [(Salest - COGSt) / Salest]

3) Asset Quality Index (AQI)

AQI = [(Total Assets - Current Assetst - PP&Et) / Total Assetst] / [(Total Assets - Current Assetst-1 - PP&Et-1) / Total Assetst-1]

4) Sales Growth Index (SGI)

SGI = Salest / Salest-1

5) Depreciation Index (DEPI)

DEPI = (Depreciationt-1/ (PP&Et-1 + Depreciationt-1)) / (Depreciationt / (PP&Et + Depreciationt))

6) Sales General and Administrative Expenses Index (SGAI)

SGAI = (SG&A Expenset / Salest) / (SG&A Expenset-1 / Salest-1)

7) Leverage Index (LVGI)

LVGI = [(Current Liabilitiest + Total Long Term Debtt) / Total Assetst] / [(Current Liabilitiest-1 + Total Long Term Debtt-1) / Total Assetst-1]

8) Total Accruals to Total Assets (TATA)

TATA = (Income from Continuing Operationst - Cash Flows from Operationst) / Total Assetst

After computing the eight variables outlined above, they can be weighted together using the following multivariate model to calculate the score:

Beneish M-Score =
-4.84
(+) 0.92 × DSRI
(+) 0.528 × GMI
(+) 0.404 × AQI
(+) 0.892 × SGI
(+) 0.115 × DEPI
(+) -0.172 × SGAI
(+) 4.679 × TATA
(+) -0.327 × LVGI

Click the link below to download a spreadsheet with an example Beneish M-Score calculation for Regeneron Pharmaceuticals Inc below:

Sector Benchmark Analysis

All rights reserved. Terms Of Use